251 related articles for article (PubMed ID: 10570433)
1. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
2. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.
Engblom P; Rantanen V; Kulmala J; Helenius H; Grènman S
Br J Cancer; 1999 Jan; 79(2):286-92. PubMed ID: 9888470
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
5. Taxane sensitivity of ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
[TBL] [Abstract][Full Text] [Related]
6. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
Raitanen M; Rantanen V; Kulmala J; Helenius H; Grénman R; Grénman S
Int J Cancer; 2002 Jul; 100(2):238-43. PubMed ID: 12115575
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer.
Aoki Y; Sato T; Tsuneki I; Watanabe M; Kase H; Fujita K; Kurata H; Tanaka K
Int J Gynecol Cancer; 2002; 12(6):704-9. PubMed ID: 12445246
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
[TBL] [Abstract][Full Text] [Related]
10. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
12. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
[TBL] [Abstract][Full Text] [Related]
14. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
15. [Docetaxel and ovarian cancer].
Ray-Coquard I
Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
20. The integration of docetaxel into first-line chemotherapy for ovarian cancer.
Kaye SB;
Int J Gynecol Cancer; 2001; 11 Suppl 1():31-3. PubMed ID: 11489000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
